Product news

Share this article:
Boehringer Ingelheim announced that the European Commission has granted marketing approval for its novel, direct thrombin inhibitor, Pradaxa (dabigatran etexilate) in all 27 EU member states. It is anticipated that Pradaxa will be launched in Germany and the UK in the coming weeks. Pradaxa is approved for the prevention of venous thromboembolic events in adults who have undergone elective total hip or total knee replacement surgery.
 
Wyeth and Progenics Pharmaceuticals received Canadian marketing approval for Relistor, a drug for the treatment of opioid-induced constipation in patients with advanced illness. Wyeth expects the drug to be available to patients in Canada within 60 days. The companies anticipate an FDA decision on Relistor by the end of April.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Genentech shift could prove costly for hospitals

Genentech will use specialty distributors rather than wholesalers, hospitals pharmacy directors have learned.

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies